Clinical Trial Update: Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant [Phase 2]

View source ↗

Summary

This clinical trial update notes a Phase 2 study evaluating binimetinib for relapsed/refractory BRAF wild-type hairy cell leukemia and its variants, currently r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hairy Cell Leukemia

Drugs mentioned

• Binimetinib (binimetinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Hairy Cell Leukemia | Phase 2 | Status: RECRUITING